Oruka Therapeutics (NASDAQ:ORKA) SVP Arjun Agarwal Sells 9,459 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 9,459 shares of the firm’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $92.23, for a total transaction of $872,403.57. Following the sale, the senior vice president owned 15,312 shares of the company’s stock, valued at $1,412,225.76. This represents a 38.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Arjun Agarwal also recently made the following trade(s):

• On Tuesday, September 15th, Arjun Agarwal sold 560 shares of Oruka Therapeutics stock. The shares were sold at an average price of $95.71, for a total transaction of $53,597.60.
• On Thursday, August 13th, Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $106.66, for a total value of $1,066,600.00.
• On Monday, July 13th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The stock was sold at an average price of $84.63, for a total value of $846,215.37.
• On Monday, June 22nd, Arjun Agarwal sold 1,587 shares of Oruka Therapeutics stock. The stock was sold at an average price of $80.95, for a total value of $128,467.65.

Oruka Therapeutics Stock Down 3.9%

ORKA stock opened at $92.20 on Wednesday. Oruka Therapeutics, Inc. has a 52-week low of $14.66 and a 52-week high of $115.51. The stock has a market cap of $6.10 billion, a price-to-earnings ratio of -45.42 and a beta of -0.34. The business has a fifty day moving average of $95.87 and a two-hundred day moving average of $72.78.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, sell-side analysts anticipate that Oruka Therapeutics, Inc. will post -2.42 EPS for the current year.

Institutional Trading of Oruka Therapeutics

Several hedge funds have recently modified their holdings of ORKA. BlackRock Inc. purchased a new stake in Oruka Therapeutics during the 2nd quarter worth about $474,916,000. Jupiter Topco LLC purchased a new position in shares of Oruka Therapeutics in the 2nd quarter valued at about $130,968,000. Remedium Capital Partners LLC boosted its stake in shares of Oruka Therapeutics by 0.9% in the 1st quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company’s stock valued at $76,796,000 after buying an additional 13,247 shares during the period. Perceptive Advisors LLC grew its position in shares of Oruka Therapeutics by 16.4% during the fourth quarter. Perceptive Advisors LLC now owns 1,476,501 shares of the company’s stock worth $44,753,000 after buying an additional 208,480 shares in the last quarter. Finally, Avidity Partners Management LP grew its position in shares of Oruka Therapeutics by 15.1% during the first quarter. Avidity Partners Management LP now owns 760,424 shares of the company’s stock worth $37,299,000 after buying an additional 100,000 shares in the last quarter. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on ORKA shares. Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. UBS Group increased their price objective on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Piper Sandler reiterated an “overweight” rating and issued a $180.00 target price on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. HC Wainwright reissued a “buy” rating and issued a $120.00 target price on shares of Oruka Therapeutics in a research report on Thursday, September 3rd. Finally, Mizuho set a $120.00 price target on Oruka Therapeutics in a research note on Thursday, September 3rd. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $133.00.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.